Lonza announced Swissmedic approval for a new aseptic drug‑product filling line in Stein (CH) designed for highly potent biologics, enhancing capacity for liquid and lyophilized vials and meeting Annex 1 GMP containment requirements. The line targets modalities including monoclonal antibodies, bispecifics and ADCs and strengthens integrated supply for clinical and commercial programs. Separately, MilliporeSigma (Merck KGaA’s North American life‑science arm) agreed to acquire the chromatography business of JSR Life Sciences to expand downstream Protein A chromatography capabilities. Together, these moves indicate ongoing CDMO and supplier consolidation as biopharma seeks more integrated, high‑containment manufacturing to support complex biologics and gene‑therapy supply chains.